Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Gastric Cancer: Update Bulletin # 3 [March 2019]

Product Code:
Publication Date:
March 2019

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the gastric cancer (GC) market, including: initiation of BeiGene's two Phase III trials with tislelizumab (BGB-A317) in locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, and unresectable, locally advanced recurrent or metastatic oesophageal squamous cell carcinoma (ESCC); initiation of Deciphera Pharmaceuticals' second Phase III study with ripretinib (DCC-2618), which is being compared against sunitinib (Sutent; Pfizer) in the second-line treatment of gastrointestinal stromal tumours (GIST); and US Food and Drug Administration approval of Taiho Oncology's Lonsurf (trifluridine + tipiracil) in patients with metastatic gastric or GEJ adenocarcinoma previously treated with at least two prior lines of chemotherapy.

Business Questions:

  • Are experts optimistic that BeiGene's tislelizumab will show benefit in the front-line setting?
  • Does tislelizumab have significant market potential?
  • Do KOLs see tislelizumab as sufficiently differentiated from other members of the anti-PD1 class?
  • What challenges will BeiGene/Celgene face to effectively market tislelizumab in Western markets?
  • Do KOLs see potential for Deciphera Pharmaceuticals' ripretinib in GIST?
  • Are the experts convinced that ripretinib compares favourably to sunitinib?
  • If ripretinib is approved, can Deciphera expect a rapid uptake in Western markets?
  • Is approval of Taiho Oncology's Lonsurf welcomed by KOLs?
  • Is safety a concern with Lonsurf?
  • What patient subgroups do experts see as Lonsurf's key markets?


All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved